NeuroSense Therapeutics Total Liabilities Growth & History (NRSN)

NeuroSense Therapeutics's total liabilities was $2.6M for fiscal 2025.

View full NeuroSense Therapeutics company overview

NeuroSense Therapeutics annual total liabilities history

NeuroSense Therapeutics annual total liabilities

Fiscal yearPeriod endedTotal liabilitiesChangeGrowth
20252025-12-31$2.6M$596,000+29.92%
20242024-12-31$2.0M−$3.1M−60.55%
20232023-12-31$5.0M$3.0M+141.51%
20222022-12-31$2.1M−$334,000−13.77%
20212021-12-31$2.4M$2.3M+1920.83%
20202020-12-31$120,000

NeuroSense Therapeutics total liabilities trends

Over the last five fiscal years, NeuroSense Therapeutics's total liabilities increased from $120,000 to $2.6M, a change of $2.5M. The latest reported quarter, Q4 2025, shows $2.6M.

About the metric

What total liabilities mean

Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.

Calculation and source

SEC-reported and calculated total liabilities

TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review NeuroSense Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about NRSN yet. Start the conversation.

Write the first post